Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 168% % -60%
Return On Equity 7.8% % -32%
Return On Assets 4.2% % -38%
Operating Margin 65% % -4.3%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $13,100,000,000 USD -4.4%
Weighted Average Number of Shares Outstanding, Basic 431,887,000 shares -3.5%
Weighted Average Number of Shares Outstanding, Diluted 559,611,000 shares -5.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,349,844,000 USD 3.7%
Research and Development Expense $402,000,000 USD 20000%
General and Administrative Expense $476,799,000 USD 109%
Costs and Expenses $817,193,000 USD 13%
Operating Income (Loss) $1,532,651,000 USD -0.72%
Nonoperating Income (Expense) $230,021,000 USD -235%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,302,630,000 USD -24%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $764,956,000 USD -33%
Earnings Per Share, Basic 1 USD/shares -32%
Earnings Per Share, Diluted 1 USD/shares -32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $938,944,000 USD -1.2%
Other Assets, Current $5,519,000 USD 11%
Assets, Current $1,849,537,000 USD 3.1%
Goodwill $924,634,000 USD
Other Assets, Noncurrent $86,585,000 USD 102%
Assets $19,347,280,000 USD 7.2%
Liabilities, Current $530,802,000 USD -55%
Other Liabilities, Noncurrent $126,944,000 USD 2175%
Liabilities $9,726,419,000 USD 25%
Retained Earnings (Accumulated Deficit) $2,304,314,000 USD -17%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $9,620,861,000 USD -6.2%
Liabilities and Equity $19,347,280,000 USD 7.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $596,076,000 USD -10%
Net Cash Provided by (Used in) Financing Activities $941,299,000 USD -344%
Net Cash Provided by (Used in) Investing Activities $503,917,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $158,694,000 USD -57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $938,944,000 USD -1.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities $138,822,000 USD 76%
Operating Lease, Liability $20,019,000 USD
Lessee, Operating Lease, Liability, to be Paid $23,171,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,776,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $4,053,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,152,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,721,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,726,000 USD
Additional Paid in Capital $4,112,538,000 USD 0.12%
Share-based Payment Arrangement, Expense $73,353,000 USD 10188%
Interest Expense $184,469,000 USD -1.8%